Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsEffects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-AnalysisDrug-resistant tuberculosis in Eastern Europe: challenges and ways forwardDoing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in NigeriaHigh frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosisPatient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in IndiaDOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisAdherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.Rapid determination of anti-tuberculosis drug resistance from whole-genome sequencesSevere adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort studyPreliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014.Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.The medical and surgical treatment of drug-resistant tuberculosis.Adverse effects of oral second-line antituberculosis drugs in children.The safety and tolerability of the second-line injectable antituberculosis drugs in children.Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa.Statin Adjunctive Therapy for Tuberculosis Treatment.Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal"Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa
P2860
Q21131083-3A339AFB-106E-42CB-8192-471F749F5E75Q26775757-97D5CDA9-9DF2-4C44-9EAB-086C52DFC87FQ26782448-BB7C2638-BFA2-42FE-9616-B52DC7C6732EQ28544462-EDDD3B5A-06EF-45A0-8509-2424B3F272D0Q28546682-D7D9CEE9-D1F6-4D79-9496-BAF05992565BQ28547430-D3015B43-90CF-467F-9EEF-0E05629AE211Q33704314-D5B4E2E1-31AF-4DF2-96CF-4CF65CE26C8DQ33926262-02A66744-C565-4CBF-8EB7-268006CFE992Q35538913-F8FA6762-F1AE-401A-AD1B-B1D4D575D7AAQ35644365-65781086-0582-4470-A8F5-B68067D23713Q36171130-887264E8-5B1E-4CC7-B4D5-063D4188E016Q36617040-FA7B0D53-FC67-454D-B990-A39CD60556B5Q37460655-3D6F5272-00D5-4F78-B486-39D3BC1124D0Q37629518-A474BC40-2D87-46E7-8ABE-2A3FEB46FFC8Q38837774-5A8D0F55-C21C-4B82-96C1-58EDD49DDF98Q38933875-44D504D3-75EC-429B-A9E8-16EC3974E0ABQ39248451-DACBA6D8-AF89-44E7-AB5C-59560C487202Q40139987-C21AB8F9-D268-41BF-ACC4-A7921CFD05E1Q40934368-4CA37174-A425-4681-86ED-D65ECAA1F30FQ42380909-7C2B7669-3B34-4F9B-A44A-F5DD208DC75FQ52707803-CDF68954-E1A9-4204-9B9C-4D38CE2C7C6AQ56927234-10E3BE7B-030F-4404-A040-F5CBBFE2A459Q58741213-CB3BD503-801D-4032-9656-62A1C9658FAF
P2860
Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Drug-associated adverse events ...... t tuberculosis in South Africa
@ast
Drug-associated adverse events ...... t tuberculosis in South Africa
@en
Drug-associated adverse events ...... t tuberculosis in South Africa
@nl
type
label
Drug-associated adverse events ...... t tuberculosis in South Africa
@ast
Drug-associated adverse events ...... t tuberculosis in South Africa
@en
Drug-associated adverse events ...... t tuberculosis in South Africa
@nl
prefLabel
Drug-associated adverse events ...... t tuberculosis in South Africa
@ast
Drug-associated adverse events ...... t tuberculosis in South Africa
@en
Drug-associated adverse events ...... t tuberculosis in South Africa
@nl
P2093
P2860
P50
P3181
P1433
P1476
Drug-associated adverse events ...... t tuberculosis in South Africa
@en
P2093
Grant Theron
Greg Symons
Karen Shean
Martin Groubusch
Motasim Badri
Paul Wilcox
Tommie C Victor
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0063057
P407
P50
P577
2013-01-01T00:00:00Z